RxDoctor Payments DataLook up a doctor →

Edwin Gar-El, MD

Family Medicine · Elkton, MDNPI 1740255728

Payments from drug & device makers

$26,074in general payments, 2019–2025

Across 1,167 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Amgen$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$6302%
  • Speaking & faculty fees$3,85015%
  • Travel & lodging$6993%
  • Food & beverage$20,71379%
  • Education$1811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)171$7,148
Amgen(2 entities)93$1,938
Novo Nordisk94$1,537
AstraZeneca59$1,234
Boehringer Ingelheim33$1,170
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC91$1,047
Lilly USA, LLC53$1,012
Pfizer36$624
Johnson & Johnson(2 entities)26$611
Merck32$546
Otsuka America Pharmaceutical, Inc.33$503
GSK20$501
Astellas Pharma US Inc23$441
Novartis25$440
Sanofi-aventis U.S. LLC21$429
Phathom Pharmaceuticals, Inc.23$380
Dexcom, Inc.7$366
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$346
Teva Pharmaceuticals USA, Inc.15$321
Axsome Therapeutics, Inc.13$288
Verona Pharma, Inc.20$288
Corium, LLC17$287
Amarin Pharma, Inc.12$286
Sanofi14$275
Medtronic4$244
Bayer12$242
Corcept Therapeutics6$210
Jazz Pharmaceuticals Inc.13$201
Radius Health, Inc.10$199
Insulet Corporation9$193
Kowa Pharmaceuticals America, Inc.12$185
Takeda Pharmaceuticals U.S.A., Inc.11$172
Biohaven Pharmaceuticals, Inc.18$159
Alkermes, Inc.7$141
Vanda Pharmaceuticals Inc.8$141
Valeritas, Inc.3$128
Antares Pharma, Inc.9$125
Idorsia Pharmaceuticals US Inc6$123
Shire North American Group Inc9$121
E.r. Squibb & Sons, L.L.C.7$112
Xeris Pharmaceuticals, Inc.6$100
VBI Vaccine (delaware) Inc.3$89
Lundbeck LLC5$83
Abbott5$79
Microport Orthopedics Inc1$71
Viatris Specialty LLC3$69
Amneal Pharmaceuticals LLC4$68
Arbor Pharmaceuticals, Inc.4$59
Adlon Therapeutics L.p.4$54
Harmony Biosciences LLC3$53
Sumitomo Pharma America, Inc.3$51
Paratek Pharmaceuticals, Inc.3$49
Hikma Pharmaceuticals USA3$49
Exact Sciences2$38
Tactile Systems Technology Inc1$37
ANI Pharmaceuticals, Inc.2$37
Nabriva Therapeutics, PLC2$37
Neurocrine Biosciences, Inc.2$33
IBSA Pharma Inc.2$29
Impel Pharmaceuticals LLC1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,074 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$165,992
Medicare patients
369
Services billed
1,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$101,889
XeljanzTofacitinib Citrate14$84,568
JardianceEmpagliflozin65$82,973
OzempicSemaglutide52$81,945
FarxigaDapagliflozin Propanediol61$66,756
JanuviaSitagliptin Phosphate45$61,088
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$57,973
MounjaroTirzepatide39$46,393
XareltoRivaroxaban50$44,700
Fiasp FlextouchInsulin Aspart (Niacinamide)12$23,073
MyrbetriqMirabegron24$22,832
Tresiba Flextouch U-200Insulin Degludec13$19,871
LinzessLinaclotide28$18,568
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,971
EntrestoSacubitril/Valsartan12$14,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz, Paxlovid$624$190,587114 claims
Boehringer IngelheimJardiance$1,170$82,97365 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,234$82,72782 claims
Novo NordiskOzempic$1,537$81,94552 claims
MerckJanuvia, Janumet Xr, Belsomra$546$79,71476 claims
GSKTrelegy Ellipta, Incruse Ellipta$501$62,38855 claims
Lilly USA, LLCMounjaro$1,012$46,39339 claims
Johnson & JohnsonXarelto$611$44,70050 claims
Astellas Pharma US IncMyrbetriq$441$22,83224 claims
AbbVieLinzess, Synthroid$7,148$20,64867 claims
NovartisEntresto$440$14,51412 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$172$7,64511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →